| value |
{"aggregator_url":"https://news.google {"aggregator_url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE55MVc2eHAtT2Znc29DbDlOZ0FpcmtWUE1VS2dISWgxTjhvZm5xUkM0U3ZqWHFUenZRaEEyemVTWEpPdE5ORjU0Tkg4TmdCaHlPOGoxaFJwYmZBYU1iWC1v?oc=5","as_of":"2026-04-08T20:43:08.238197+00:00","canonical_url":"https://www.gstatic.com/_/mss/boq-dots/_/ss/k=boq-dots.DotsSplashUi_desktop_ms.OYgPNdDf9Nc.L.X.O/am=GAIFAAAADpgFDCgAAQ/d=1/ed=1/rs=ALs0n2OYSmDAUDetpsORI83j3dpsv55GJQ/m=syndicationarticleview,_b,_tp","enrichment":{"aggregator_url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE55MVc2eHAtT2Znc29DbDlOZ0FpcmtWUE1VS2dISWgxTjhvZm5xUkM0U3ZqWHFUenZRaEEyemVTWEpPdE5ORjU0Tkg4TmdCaHlPOGoxaFJwYmZBYU1iWC1v?oc=5","article_chars":5000,"article_truncated":true,"blocked_reason":null,"candidate_id":"sc_2bd834a0a04eb17f","canonical_host":"gstatic.com","canonical_is_aggregator":true,"canonical_url":"https://www.gstatic.com/_/mss/boq-dots/_/ss/k=boq-dots.DotsSplashUi_desktop_ms.OYgPNdDf9Nc.L.X.O/am=GAIFAAAADpgFDCgAAQ/d=1/ed=1/rs=ALs0n2OYSmDAUDetpsORI83j3dpsv55GJQ/m=syndicationarticleview,_b,_tp","content_type":"text/html; charset=utf-8","enriched_at":"2026-04-09T22:11:19.353139+00:00","extraction_method":"heuristic","fetched_description":"","fetched_title":"","final_url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE55MVc2eHAtT2Znc29DbDlOZ0FpcmtWUE1VS2dISWgxTjhvZm5xUkM0U3ZqWHFUenZRaEEyemVTWEpPdE5ORjU0Tkg4TmdCaHlPOGoxaFJwYmZBYU1iWC1v?oc=5&hl=en-US&gl=US&ceid=US:en","html_truncated":true,"paywall_likely":false,"publisher_domain":"nature.com","publisher_resolution":"payload_source_domain","requested_url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE55MVc2eHAtT2Znc29DbDlOZ0FpcmtWUE1VS2dISWgxTjhvZm5xUkM0U3ZqWHFUenZRaEEyemVTWEpPdE5ORjU0Tkg4TmdCaHlPOGoxaFJwYmZBYU1iWC1v?oc=5","source_event_id":"evt_22343cce396f","source_quality":"high","status_code":200,"version":"signal_enrichment_v2"},"fp":"bcb2c39ab19a635b","published_at":"2026-04-08T19:30:00+00:00","publisher_domain":"nature.com","signal_understanding":{"analysis_basis":"headline_and_summary","claim_confidence":0.62,"dates_mentioned":[],"entities":[{"asset_class":"media","name":"Nature","relevance":"high","symbol":"","type":"publisher"},{"asset_class":"healthcare","name":"GLP-1 receptor agonist weight-loss drugs","relevance":"high","symbol":"","type":"drug_class"},{"asset_class":"biotech_target","name":"GLP-1 receptor","relevance":"high","symbol":"","type":"biological_target"},{"asset_class":"media","name":"BBC","relevance":"medium","symbol":"","type":"publisher"},{"asset_class":"media","name":"The Washington Post","relevance":"medium","symbol":"","type":"publisher"},{"asset_class":"media","name":"The Guardian","relevance":"medium","symbol":"","type":"publisher"}],"event_type":"research","information_gaps":["The cleaned article text provided contains only page styling/HTML/CSS and does not include the actual article content, methods, effect sizes, or specific gene names/variants.","No details are provided on study design (e.g., cohort size, ancestry coverage), magnitude of predictive performance, or clinical actionability (e.g., whether testing is recommended).","Near-term timing for translation into clinical practice (guidelines, trials, regulatory steps) is not specified in the provided text."],"key_facts":["Nature headline indicates genetic factors (genes) are linked to differences in how well obesity drugs work for some people.","The provided source summary states genetic predictors relate to GLP-1 receptor agonist weight-loss outcomes and side effects.","The provided source summary frames the finding as explaining variability in results from weight-loss injections."],"numeric_claims":[],"primary_claim":"Genetic variants can predict who responds better to GLP-1 receptor agonist weight-loss drugs and who is more likely to experience side effects.","relevance_score":0.72,"sentiment":"neutral","source_quality":"high","summary":"Nature reports genetic clues that may explain why GLP-1 receptor agonist (obesity) drugs produce different weight-loss outcomes and side-effect profiles across individuals.","topics":["obesity","GLP-1 receptor agonists","pharmacogenomics","genetics","weight-loss response variability","side effects prediction"]},"source":"Nature","source_domain":"nature.com","source_url":"https://www.nature.com","summary":"Why obesity drugs work better for some people: these genes hold clues Nature Genetic predictors of GLP1 receptor agonist weight loss and side effects Nature Weight-loss drugs: Who benefits most and why? BBC If you aren\u2019t losing weight with GLP-1 drugs, this may be one reason why The Washington Post Genetics may help explain why results from weight-loss jabs vary, say scientists The Guardian","title":"Why obesity drugs work better for some people: these genes hold clues - Nature","url":"https://www.gstatic.com/_/mss/boq-dots/_/ss/k=boq-dots.DotsSplashUi_desktop_ms.OYgPNdDf9Nc.L.X.O/am=GAIFAAAADpgFDCgAAQ/d=1/ed=1/rs=ALs0n2OYSmDAUDetpsORI83j3dpsv55GJQ/m=syndicationarticleview,_b,_tp"}... |